Virus News and Research

Latest Virus News and Research

HHS announces contract awards for up to 120,000 treatment courses of intravenous antiviral drugs

The U.S. Department of Health and Human Services (HHS) today announced contract awards for up to 120,000 treatment courses of intravenous (IV) antiviral drugs to help treat hospitalized 2009 H1N1 influenza patients.

6 Nov 2009

GenVec and SAIC-Frederick signs contract to develop influenza and HIV vaccines

GenVec, Inc, announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

5 Nov 2009

U.S. health officials offer no prediction of when all high-risk groups will have access to H1N1 vaccine

U.S. health officials briefing Congress on Wednesday would not outline a timeline for when enough H1N1 (swine flu) vaccines would be available to reach all high-risk populations in the country, the Washington Post reports.

5 Nov 2009

Oncolytics Biotech reports financial results for the third quarter of 2009

Oncolytics Biotech Inc. today announced its financial results for the three and nine-month periods ended September 30, 2009.

5 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Japanese data suggests a protocol for schools to follow during H1N! pandemic

As flu season approaches, parents around the country are starting to face school closures. But how bad should an influenza outbreak be for a school to shut down? A study led by epidemiologists John Brownstein, PhD, and Anne Gatewood Hoen, PhD of the Children's Hospital Boston Informatics Program, in collaboration Asami Sasaki of the University of Niigata Prefecture (Niigata, Japan), tapped a detailed set of Japanese data to help guide decision making by schools and government agencies.

5 Nov 2009

Phadia offers ImmunoCAP, a reliable test to accurately diagnose the severity of egg allergy

The World Health Organization recently declared H1N1 swine flu a global pandemic, resulting in the creation of rigorous vaccination programs worldwide. Children are among those considered particularly susceptible to contracting swine flu and are viewed as a top priority in receiving this vaccine.

5 Nov 2009

Online self-assessment tool on MayoClinic.com helps assess flu symptoms

The flu symptoms self-assessment tool on MayoClinic.com helps you assess whether you or your loved ones have some form of flu, or just a cold. If you possibly or likely have the flu, you'll also learn whether antiviral medication is an option. And you can check a concise list of high-risk groups who should seek medical attention for the flu.

5 Nov 2009

InterMune seeks FDA marketing approval for pirfenidone

InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.

5 Nov 2009

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $208 million to two programs that support research to better understand the human immune response to emerging and re-emerging infectious diseases, including those that may be introduced into a community through acts of bioterrorism.

5 Nov 2009

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.

5 Nov 2009

House legislation seeks 5 days of sick leave for workers

In an effort to rein in the spread of the H1N1 Flu, Representative George Miller, the chairman of the House Education and Labor Committee, introduced legislation on Tuesday that would guarantee five paid sick days for workers sent home by their employers with a contagious illness. Mr. Miller, Democrat of California, voiced concern that more than 40 million workers did not have paid sick days and that many workers coming into contact with public — like restaurant or school cafeteria employees — would go to work with H1N1 and spread the virus if they could not afford to stay home.

5 Nov 2009

One Health Commission summit to focus on emerging infectious diseases

The growing threat of the H1N1 pandemic and West Nile virus -- as well as other emerging zoonotic, food, or waterborne diseases and environmental changes -- has prompted experts to look for solutions to the increasingly integrated problems among animal, human, and environmental health.

5 Nov 2009

News outlets examine international efforts to contain H1N1

A WHO official on Tuesday backed the Afghan government's decision to declare H1N1 (swine flu) a health emergency, forcing the closure of all schools in the country for three weeks in an effort to contain the virus, IRIN reports.

4 Nov 2009

GenVec receives FDA orphan drug designation for TNFerade

GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.

4 Nov 2009

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.

4 Nov 2009

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has advanced to the RNAi therapeutic collaboration stage of its landmark alliance with Roche formed in 2007.

4 Nov 2009

Henry Schein announces record financial results for third quarter 2009; reports net sales growth in local currencies

Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended September 26, 2009.

4 Nov 2009

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected. In this clinical trial to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers treated patients - both treatment naive and experienced patients - with a twice daily oral combination therapy of a nucleoside polymerase and protease inhibitor.

4 Nov 2009

Virus News and Research

Latest Virus News and Research

HHS announces contract awards for up to 120,000 treatment courses of intravenous antiviral drugs

GenVec and SAIC-Frederick signs contract to develop influenza and HIV vaccines

U.S. health officials offer no prediction of when all high-risk groups will have access to H1N1 vaccine

Oncolytics Biotech reports financial results for the third quarter of 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Japanese data suggests a protocol for schools to follow during H1N! pandemic

Phadia offers ImmunoCAP, a reliable test to accurately diagnose the severity of egg allergy

Online self-assessment tool on MayoClinic.com helps assess flu symptoms

InterMune seeks FDA marketing approval for pirfenidone

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

House legislation seeks 5 days of sick leave for workers

One Health Commission summit to focus on emerging infectious diseases

News outlets examine international efforts to contain H1N1

GenVec receives FDA orphan drug designation for TNFerade

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Henry Schein announces record financial results for third quarter 2009; reports net sales growth in local currencies

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in